Go to Health Care Provider version
| Diagnosis | Neuroblastoma, Osteosarcoma | Study Status | Closed to enrollment |
| Phase | I |
| Age | Child, Adult - (up to 35 Years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Dinutuximab: intravenous
Magrolimab: intravenous |
| Last Posted Update | 2024-02-13 |
| ClinicalTrials.gov # | NCT04751383 |
International Sponsor
COG Pediatric Early Phase Clinical Trials Network (PEP-CTN)
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel A. Morgenstern
BC Children's Hospital - Dr. Rebecca Deyell
Centres
Medical contact
Rebecca Deyell
Social worker/patient navigator contact
Ilana Katz
Clinical research contact
Hem/Onc/BMT Clinical Trials Unit
Study Description
The purpose of this study is to determine the best dose, benefits and/or side effects of 2 drugs (magrolimab and dinutuximab) when given in combination to treat neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory), or osteosarcoma that has come back (relapsed). These drugs (magrolimab and dinutuximab) interfere with the ability of cancer cells to grow and spread, using them in treatment may stop or shrink cancer growth in cases of neuroblastoma and osteosarcoma.
An additional aim of this study is determining the safety of these drugs (magrolimab and dinutuximab) when given after surgery to remove tumors from the lungs.
Inclusion Criteria
- Age between 1 and 35 years
- Patients must have:
- neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory) or
- osteosarcoma that has come back (relapsed)
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
